Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Essential Hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    235 result(s) found for: Essential Hypertension. Displaying page 6 of 12.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2007-002421-68 Sponsor Protocol Number: 1235.6 Start Date*: 2007-10-05
    Sponsor Name:Boehringer Ingelheim Ltd
    Full Title: An eight-week randomised, 3-arm, double-blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10mg versus amlo...
    Medical condition: essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) GB (Completed) AT (Completed) ES (Completed) BG (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-012966-30 Sponsor Protocol Number: DSE-SEV-02-09 Start Date*: 2009-11-16
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: “Eficacia de Sevikar® comparado con la combinación de Perindoprilo/Amlodipino sobre la Presión Arterial Central, en Pacientes con Hipertensión moderada a severa - SEVITENSION”
    Medical condition: Eficacia de Sevikar® comparado con la combinación de Perindoprilo/Amlodipino sobre la Presión Arterial Central, en Pacientes con Hipertensión moderada a severa - SEVITENSION
    Disease: Version SOC Term Classification Code Term Level
    9 10015491 Essential hypertension, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002265-36 Sponsor Protocol Number: CHDR1518 Start Date*: 2015-10-22
    Sponsor Name:Centre for Human Drug Research
    Full Title: A randomized, double blind, crossover, placebo controlled class-room experiment to assess the pharmacodynamics and pharmacokinetics of metoprolol in healthy volunteers with different polymorphism o...
    Medical condition: Influence of CYP2D6 polymorphism on metoprolol pharmacokinetics and pharmacodynamics in human volunteers
    Disease: Version SOC Term Classification Code Term Level
    18.0 10007541 - Cardiac disorders 10007521 Cardiac arrhythmias HLGT
    18.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001176-67 Sponsor Protocol Number: MEC-66108-2007 Start Date*: 2009-10-16
    Sponsor Name:Dr. Antonio Osuna Ortega
    Full Title: Biodisponibilidad de quercetina bajo distintas formas de administración y sus implicaciones sobre el efecto antihipertensivo
    Medical condition: Several epidemiologic studies have reported an inverse association between dietary flavonoid intake and mortality related to ischaemic heart disease. Our studies show that quercetin, the main dieta...
    Disease: Version SOC Term Classification Code Term Level
    9 10015489 Essential hypertension, benign LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001596-23 Sponsor Protocol Number: KCT06/2017-PRECIOUS Start Date*: 2017-11-30
    Sponsor Name:Krka, d.d., Novo mesto
    Full Title: Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in newly diagnosed and uncont...
    Medical condition: Newly diagnosed and uncontrolled patients with essential arterial hypertension.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002252-33 Sponsor Protocol Number: CSPP100A2304 Start Date*: 2005-01-28
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in p...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013165-25 Sponsor Protocol Number: TAK-491_109 Start Date*: 2010-02-26
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents with Hypertension and Healthy Adults
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-018436-41 Sponsor Protocol Number: Bay 63-2521/14554 Start Date*: 2010-05-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: Acute hemoDynamic effects of RIociguat (BAY 63-2521) in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE 1): A randomized, double-blind, placebo-controlled, sin...
    Medical condition: Pulmonary hypertension associated with diastolic heart failure
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037405 Pulmonary hypertension primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) CZ (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000856-34 Sponsor Protocol Number: CSPP100A2316 Start Date*: 2005-08-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ve...
    Medical condition: left ventricular hypertrophy in overweight patients with essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006719-66 Sponsor Protocol Number: CVAA 489 A FR01 Start Date*: 2007-06-01
    Sponsor Name:Novartis Pharma S.A.S.
    Full Title: Efficacité d’un traitement par l’association amlodipine et valsartan en monoprise vespérale ou matinale, chez des Patients présentant une HTA Essentielle moyenne à modérée, non contRôlée par amlodi...
    Medical condition: HTA essentielle
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004254 Benign essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003672-31 Sponsor Protocol Number: KCT05/2017-UNIFY Start Date*: 2019-01-03
    Sponsor Name:KRKA, d.d., Novo mesto
    Full Title: Fixed-dose combination of rosuvastatin and valsartan for dual target achievement in patients with hypertension and hyperlipidaemia (UNIFY)
    Medical condition: Patients with mild to moderate essential arterial hypertension AND primary hypercholesterolemia or mixed dyslipidaemia (LDL-c < 4.9 mmol/L or <189.5 mg/dl) with moderate, high or very high risk for...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10062060 Hyperlipidaemia PT
    20.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003204-40 Sponsor Protocol Number: PATHBP_2013 Start Date*: 2014-01-20
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Paracetamol treatment in hypertension: effect on blood pressure
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10005729 Blood pressure ambulatory PT
    14.1 10047065 - Vascular disorders 10020775 Hypertension arterial LLT
    14.1 10022891 - Investigations 10005756 Blood pressure systolic PT
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10022891 - Investigations 10005735 Blood pressure diastolic PT
    14.1 10022891 - Investigations 10033762 Paracetamol LLT
    14.1 10022891 - Investigations 10005727 Blood pressure PT
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003975-38 Sponsor Protocol Number: TERPAH-001 Start Date*: 2007-11-22
    Sponsor Name:Ergonex Pharma GmbH
    Full Title: Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective P...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000674-18 Sponsor Protocol Number: AR14.001 Start Date*: 2015-05-26
    Sponsor Name:Arbor Pharmaceuticals, LLC.
    Full Title: A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With ...
    Medical condition: primary or secondary hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.1 10047065 - Vascular disorders 10036695 Primary hypertension LLT
    18.1 10047065 - Vascular disorders 10039834 Secondary hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-004014-16 Sponsor Protocol Number: CSPP100A2313 Start Date*: 2005-04-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in patients wi...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002090-12 Sponsor Protocol Number: Ilocard Start Date*: 2009-03-04
    Sponsor Name:Hospital of the university of munich
    Full Title: Effect of Iloprost inhalation before and during extracorporeal circulation (ECC) on perioperative morbidity and outcome in high risk cardiac surgical patients
    Medical condition: In this study effects of the intra operative, prophylactic inhalation of Iloprost (Ventavis) before and during extracorporal circulation on perioperative morbidity and outcome in high risk cardiac ...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002621-23 Sponsor Protocol Number: SPV100A2301 Start Date*: 2006-09-28
    Sponsor Name:Novartis Pharma Services Ag
    Full Title: A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ valsartan 320 mg in patients with essential hypertension.
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-003199-23 Sponsor Protocol Number: CSAH100A2302 Start Date*: 2008-09-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to seve...
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) LT (Completed) LV (Completed) SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005843-93 Sponsor Protocol Number: CYT006-AngQb 02 Start Date*: 2008-02-21
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccin...
    Medical condition: Mild to moderate essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007516-28 Sponsor Protocol Number: CYT006-AngQb 03 Start Date*: 2008-06-06
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vac...
    Medical condition: Mild to moderate essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Aug 03 08:37:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA